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Pramlintide in the Management of Obesity
Melissa C. Jones1, Heather F. DeBellis2 and Kimberly L. Tackett1
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Abstract: Obesity is a common problem that can lead to numerous comorbid conditions, including Type 2 diabetes.  Currently, there are 
few pharmacologic options available to help obese patients lose weight. Pramlintide is an injectable, amylin analogue that is indicated 
in patients with Type 1 and Type 2 diabetes for use in conjunction with insulin to improve glycemic control.  In addition to helping 
patients decrease hemoglobin A1c levels, pramlintide has also been shown to minimize weight gain, especially in patients with Type 2 
diabetes.  Studies have been conducted in various patient types, including those patients without diabetes, and the drug tends to have a 
positive effect on weight loss.  It appears that the drug is well tolerated in patients without diabetes; however, current studies have been 
conducted in small patient populations.  Additional research needs to be carried out to determine if the drug is a viable option for obese 
patients who have failed to respond to other weight loss products.
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Obesity is a significant problem that can lead to mul-
tiple co morbid conditions. According to the Centers 
of Disease Control (CDC), in 2008 only one state, 
Colorado, had an incidence of obesity less than 20 
percent.1 There are few approved weight loss agents 
available, which has prompted researchers to look 
for alternatives to treat obesity. One such product is 
pramlintide. Pramlintide is an amylin analogue used 
in the treatment of diabetes. Amylin analogues have 
been shown to facilitate weight loss in patients with 
diabetes; therefore, they may be a viable therapeutic 
option in other patients where weight loss is impera-
tive. This article will focus on the weight loss effect 
of pramlintide in patients with diabetes, due to the 
fact that studies in obese patients without diabetes are 
minimal. However, the available studies in patients 
without diabetes will be discussed.
Pramlintide
Pramlintide is classified as an amylin analogue.2 
Amylin is secreted by the B-cells in the pancreas 
in conjunction with insulin secretion. Like Amylin, 
pramlintide suppresses hepatic glucagon secretion 
leading to a decrease in hepatic glucose production. 
In addition, it also slows gastric emptying, resulting 
in a decrease in the amount of glucose that enters the 
circulation postprandially. It also may promote a feel-
ing of satiety, leading to a reduction in caloric intake.3 
Pramlintide is administered subcutaneously and has 
a bioavailability of 30%–40%. Peak plasma levels 
are achieved within 20 minutes after injection and 
the half-life is approximately 48 minutes. The dura-
tion of effect is 3 hours and the product is primarily 
eliminated in the urine; however, dosage adjustments 
in patients with renal insufficiency are not required. 
Pramlintide must be given in conjunction with insulin; 
however, it cannot be mixed with insulin and should 
be given in a site that is away from the concomitant 
insulin injection site. The initial dose in patients with 
Type 2 diabetes is 60 mcg, just prior to meals, titrating 
after 3–7 days to 120 mcg. When initiating therapy all 
insulin doses should be decreased by 50% to avoid 
hypoglycemia.
Clinical Efficacy
The main focus of this clinical efficacy section is 
to highlight the weight reduction effects of amy-
lin replacement with pramlintide therapy. For this 
purpose, the primary emphasis is placed on trials 
evaluating pramlintide use in patients with both type1 
and type 2 (insulin-treated and noninsulin-treated) 
diabetes as well as in obese non-diabetic patients. 
Pramlintide is currently only indicated for use in 
patients with diabetes as adjunct therapy who are 
using mealtime insulin and have not achieved opti-
mal blood glucose control even with increasing insu-
lin treatment.4
Pramlintide Use in Patients  
with Type 1 Diabetes
Only about 10% of type 1 patients achieve target A1c 
levels; however, intensification of insulin therapy is 
usually accompanied by an increased incidence of 
hypoglycemia and weight gain.5 To date there have 
been three clinical trials6–8 and a pooled analysis9 
evaluating pramlintide’s efficacy in type 1 diabetes 
patients, which are summarized in Table 1. Long-term 
clinical trials ranging from 29 to 52 weeks have 
demonstrated a statistically significant weight loss 
in type 1 patients. A 29-week dose escalation study 
evaluated pramlintide doses ranging from 15 mcg 
to 60 mcg administered with meals on changes in 
weight associated with reduction in A1c.8 Doses were 
titrated by 15-mcg weekly based on whether patients 
reported the occurrence of nausea. Patients treated 
with pramlintide plus insulin achieved a significant 
reduction in mean body weight (−1.3 ± 0.30 kg) 
when compared to those patients treated with pla-
cebo plus insulin (+1.2 ± 0.24 kg). A 52-week study 
also demonstrated reduction in weight with the addi-
tion of pramlintide to insulin therapy in type 1 dia-
betes patients.7 The efficacy portion of the clinical 
trial evaluated two dosages of pramlintide, 60 mcg 
with meals and 60 mcg four times daily in addition 
to insulin therapy. Patients treated with pramlint-
ide in addition to insulin experienced a significant 
reduction in body weight as compared to placebo 
plus insulin treated patients. An additional long-term 
study, published only in abstract, concluded that the 
addition of pramlintide to insulin therapy improved 
glucose and weight control in patients with type 1 
diabetes.10
A randomized study documented weight loss in 
subjects randomized to treatment with pramlintide 
Pramlintide and obesity
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added on to insulin therapy.6 In the 52-week open-label 
extension portion of the study, addition of pramlintide 
to the patients previously randomized to placebo 
resulted in a progressive reduction in mean body 
weight similar to that seen in patients originally ran-
domized to pramlintide. By week-65 of the open-
label extension, patients in both groups achieved 
similar changes in weight loss, but those patients 
originally randomized to the pramlintide treatment 
group tended to regain weight after this week. The 
lack of a placebo-control group during the open-label 
extension does make it difficult to determine if this 
was significant.
A pooled analysis was performed to determine 
the safety and efficacy of pramlintide as adjunctive 
therapy in type 1 diabetes patients.9 This analysis 
concluded that the addition of pramlintide to insulin 
therapy aided these patients in reaching glycemic tar-
gets without experiencing weight gain or additional 
risk of hypoglycemia.
Pramlintide Use in Patients  
with Type 2 Diabetes
Table 2 evaluates the clinical studies which added 
pramlintide therapy to pre-existing insulin regimens 
in type 2 diabetes patients. The parameters outlined 
in the table include the reference, number of subjects, 
patient population, study design, study duration, dose 
of pramlintide administered during the trial, the mean 
change in body weight from baseline, the significance, 
and severe hypoglycemia incidence rates.11–15
To date, there have been three long-term clinical 
trials conducted to evaluate the use of pramlintide in 
insulin-treated type 2 diabetes patients.11,12,16 These stud-
ies have shown that initiating pramlintide as an adjunct 
to insulin therapy augments overall blood glucose con-
trol, while abating weight gain and severe hypoglyce-
mia, both of which are typically associated with titrating 
insulin doses. The three long-term clinical studies also 
showed statistically significant weight reduction at vary-
ing pramlintide doses and dosing regimens. Most nota-
bly, these studies also documented that the decrease in 
A1c levels was found unrelated to the extent of weight 
reduction reported. The subjects randomized in these 
clinical trials are representative of a typical US type 2 
diabetes patient population due to their broad range of 
baseline glycemic control and body weight.
A pooled post hoc analysis of two long-term clinical 
trials12,16 was conducted. The post hoc analysis looked 
at the potential weight reduction effects of pramlint-
ide therapy in overweight and obese insulin-treated 
type 2 diabetes patients.13 They pooled patients with an 
entry BMI  25 kg/m2 to determine the effectiveness 
of pramlintide 120 µg twice daily given before meals 
in reducing body weight. Results from this analysis 
showed that roughly three times the number of pram-
lintide-treated patients exhibited a 5% decrease in 
body weight compared to the placebo group (9% vs. 
3%, p = 0.0005) as well as an associated decrease in total 
daily insulin use (r = 0.39, p  0.0001). Therefore, this 
analysis concluded that pramlintide as adjunct therapy 
could be a potential treatment option for overweight 
and obese insulin-treated type 2 diabetes patients desir-
ing weight reduction along with resultant decreases in 
total daily insulin doses.
Maggs et al carried out a pooled post hoc analysis of 
two long-term clinical trials previously discussed in this 
section.14 This post hoc analysis evaluated the effects 
of varying pramlintide doses and dosing regimens in 
Caucasian, African American and Hispanic insulin-
treated type 2 diabetes patients. Patients were pooled 
according to their ethnicity to determine changes from 
baseline to week 52 in body weight. Results illustrated a 
reduction in weight for the pramlintide-treated patients 
regardless of ethnicity (placebo-corrected treatment 
effect at week 52: −2.6 kg, p  0.0001). This study dem-
onstrates that there are no distinct differences between 
African Americans and Hispanics when compared to 
Caucasians regarding results of pramlintide treatment, 
and that each of the three ethnic groups included were 
positively affected by pramlintide’s ability to decrease 
body weight.
A dose-escalating clinical study was conducted 
to assess various pramlintide doses and dosing 
regimens in basal insulin-treated type 2 diabetes 
patients.15 These subjects did not reach desired gly-
cemic control with insulin glargine alone or in com-
bination with oral anti-diabetic agents (metformin, 
sulfonylurea, and/or thiazolidinedione). Mealtime 
insulin was not used during the clinical trial, so the 
findings from the study can be used to determine the 
effectiveness of pramlintide in patients using only 
a regimen of basal insulin. This trial reported two 
co primary endpoints, first the change in A1c from 
Pramlintide and obesity
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baseline to week 16 as well as a dichotomous 
composite endpoint evaluating the number of 
patients meeting all of the following at week 16: 
1) A1c  7% or an A1c reduction from baseline 
0.5%, 2) mean daily postprandial glucose (PPG) 
increments 40 mg/dL, 3) no weight gain, and 4) 
no severe hypoglycemia. A greater number of pram-
lintide-treated patients than placebo group patients 
reached the composite endpoint (25% vs. 7%, 
p  0.001). Weight loss was noted in the pramlint-
ide treatment group compared to the placebo group 
(−1.6 ± 0.3 kg vs. +0.7 ± 0.3 kg, p  0.0001), and 
no severe hypoglycemia was reported. The results 
from this clinical trial concluded that glycemic and 
weight control were improved by utilizing pram-
lintide in patients with type 2 diabetes who were 
previously uncontrolled on basal insulin alone or in 
combination with oral antidiabetic agents. However, 
due to this clinical study’s relatively short duration 
of length (only 16 weeks), other related trials need 
to be conducted for these results to be considered 
definitive and clinically relevant.
According to the 6 clinical trials reviewed,11–16 adding 
pramlintide to varying insulin regimens in insulin-treated 
type 2 diabetes patients could potentially help these 
patients achieve weight loss. It appears adding pram-
lintide as adjunct therapy to insulin may facilitate glyce-
mic and weight control for these patients at the expense 
of increasing the amount of injections these patients 
receive each day, but without increasing the risk of 
severe hypoglycemia.
Pramlintide Use in Obesity
To date, there have been two clinical trials conducted 
to assess the anti-obesity properties of amylin replace-
ment with varying doses of pramlintide in patients 
with diabetes.17,18 They specifically note pramlintide’s 
effect on satiety and food intake in regard to the magni-
tude of resultant weight loss. Between the two studies, 
the patient populations evaluated include obese and 
nonobese insulin-treated type 2 diabetes patients, obese 
noninsulin-treated type 2 diabetes patients, and obese, 
healthy, patients.
A single-center, randomized, double-blind, placebo-
controlled, 2-period crossover study was performed to 
determine the effect of a single dose of pramlintide 120 µg 
on satiety and food intake.17 Subjects randomized were 
either male obese or nonobese insulin-treated type 2 
diabetes patients (n = 14) or male obese nondiabetic 
patients (n = 16). After an overnight fast, the pramlintide 
or placebo dose was administered, and was followed by 
a standardized preload meal which was to be ingested 
within 3 minutes. The preload meal consisted of about 
189 kcal, 6 g protein, 36 g carbohydrate and 3 g fat. 
Then one hour after the pramlintide or placebo dose 
was administered, subjects were offered an unlimited 
buffet meal for the next 45 minutes. The buffet included 
sandwiches, fruit, yogurt, fruit salad, custard, juice and 
coffee. Energy intake, meal duration and hunger ratings 
were analyzed. For the insulin-treated type 2 diabetes 
patients, the total energy intake was 829 ± 72 kcal in 
the placebo group and 627 ± 75 kcal in the pramlint-
ide group. There was a reduction of 202 ± 64 kcal or 
by about 23% ± 8% (p  0.01) for the insulin-treated 
type 2 diabetes patients. For the obese, nondiabetic 
patients, the total energy intake was 1,128 ± 81 kcal in 
the placebo group and 958 ± 100 kcal in the pram-
lintide group. There was a reduction of 170 ± 68 kcal 
or by about 16% ± 6% (p  0.02) for the obese nondia-
betic patients. There was not a statistically significant 
difference between the study groups in regards to meal 
duration, feelings about hunger, or feelings of fullness. 
During this trial, there were no reports of hypoglycemia. 
The results of this trial propose that pramlintide may 
be linked to a reduction in caloric intake which elicits 
weight reduction. However, this study only included 
a small sample size and other further studies are war-
ranted at this time.
A randomized, double-blind, placebo-controlled, 
multicenter, phase 2, dose-escalating clinical trial was 
conducted to assess the anti-obesity effect of increased 
doses of pramlintide in obese subjects either with 
noninsulin-treated type 2 diabetes or without diabe-
tes.18 There were 204 patients randomized to either 
the placebo group (n = 67) or the pramlintide treat-
ment group (n = 137). This four phase study consisted 
of a 1-week lead in period with placebo, a 4-week 
period where the pramlintide dose was increased, a 
12-week maintenance period, and an 8-week follow 
up period. Pramlintide treatment was initiated at 60 
µg three times daily before meals and increased in 
30 µg increments every 3 days to a maximum daily 
dose of 240 µg. Lifestyle modification was not used 
during the study. Eighty-eight percent of patients 
reached a dose of 240 µg three times daily, and 8% 
reached a dose of 180 µg three times daily. In contrast 
Pramlintide and obesity
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to placebo-treated patients who did not experience a 
significant weight loss, 31% of patients in the treat-
ment group experienced a 5% weight loss at week 
16 (p  0.001). At the end of the study, participants 
received a questionnaire in which the majority of 
the pramlintide treatment group responded that they 
thought the medication helped them control their 
weight and appetite, and that they believed the benefits 
of the medication outweighed any problems with the 
injections. They also noted that the medication made 
them feel better. Even though the pramlintide doses 
used in the study were higher than the recommended 
dose for patients with diabetes, the most common side 
effects were nausea (38%) and injection site events 
(43%). Also, there were no reports of moderate to 
severe hypoglycemia, only mild episodes noted (8%). 
This study suggests that higher pramlintide doses are 
well tolerated in obese patients.
Further research may broaden the patient popula-
tion in which amylin replacement with pramlintide 
therapy could be utilized as well as possibly treating 
obesity in otherwise healthy patients.
Studies in Other Patient Types
Although the majority of clinical trials are conducted 
in patients with diabetes, a few trials have investigated 
the use of pramlintide in healthy patients. One study 
was conducted in 411 obese subjects without diabetes, 
BMI between 30 and 50 kg/m2 and waist circumfer-
ence 102 cm for men and 88 cm for women.19 The 
patients were enrolled in an initial 4 month, random-
ized, double-blind, placebo-controlled, dose-ranging 
study and assigned to receive placebo three times per 
day or pramlintide 120, 240, or 360 mcg two or three 
times daily. At the end of 4 months, patients contin-
ued their pre-assigned treatment dose for an additional 
8 months if they did not significantly deviate from the 
protocol and agreed to the continuation. Patients also 
participated in an individualized, lifestyle intervention 
program throughout the trial. At the end of 4 months, 
weight loss in the placebo group averaged 2.8 +/− 0.8 kg 
compared to an average range of 3.8 +/− 0.7 to 6.1 
+/− 0.8 kg in the treatment arms. Those patients tak-
ing 120 mcg 3 times per day and 360 mcg 2–3 times 
per day achieved statistically significant reductions in 
weight. In addition, waist circumference also decreased 
in a number of the groups. Nausea was the most com-
mon side effect reported, with incidence increasing 
in proportion to dosing increases; however, in most 
cases nausea subsided with continued use of the drug. 
At 12 months, 40% of patients treated with pram-
lintide 120 mcg three times a day and 43% of those 
treated with 360 mcg twice a day experienced a 10% 
weight loss compared to 12% in the placebo group.
A few other studies have been conducted; however, 
the number of patients in these studies is minimal. 
A single-center, randomized, double-blind, placebo-
controlled, cross-over study was conducted in fif-
teen healthy, normal weight subjects.20 Subjects were 
exposed to a buffet meal test on two occasions. Sub-
jects were instructed to fast overnight and the next 
morning were given pramlintide 30 mcg or placebo 
followed by a standardized pre-load meal. One hour 
later they were offered a buffet meal at which time 
caloric intake and meal duration were measured. Sub-
jects given pramlintide had a reduced total caloric 
intake of 221 +/− 101 kcal (p = 0.05) as compared to 
placebo at the buffet meal. Meal duration was reduced 
by 5.1 +/− 1.4 minutes (p  0.005) for patients 
taking pramlintide when compared to placebo. The 
study indicates that pramlintide may have an effect 
on quantity of food intake and duration of meals; 
thereby, adding to the evidence that pramlintide may 
affect satiety.
Safety
The most common adverse event of pramlintide reported 
in clinical trials of type 1 and type 2 diabetes patients 
as well as obese patients without diabetes were gastro-
intestinal related. The incidence is higher when start-
ing therapy with pramlintide and may be reduced with 
gradual titration. Nausea was the most common event 
cited in clinical trials, but anorexia and vomiting were 
also reported.2,4 Nausea does have a high rate of recur-
rence, and is the primary reason for subject withdrawal 
in pramlintide treated patients during long-term con-
trolled trials.21
A barrier to diabetic patients maintaining tight 
glycemic control, A1c of  6.5% to 7%, is fear of  hy-
poglycemia. Prescribing information for pramlintide 
does contain a boxed warning stating that pram-
lintide has been associated with an increased risk 
of insulin-induced severe hypoglycemia in type 1 
patients. This event is likely seen within three hours 
following the injection of pramlintide,4,21 but clini-
cal studies have demonstrated that pramlintide does 
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not alter the counter-regulatory hormonal response to 
insulin-induced hypoglycemia.22,23 Hypoglycemia is 
the leading cause of serious adverse events reported 
in both type 1 diabetes trials (9% pramlintide vs. 4% 
placebo) and type 2 diabetes trials (2% pramlintide 
vs. 1% placebo).21 The occurrence of hypoglycemia 
in pramlintide treated patients was most common 
during the first month.4 The incidence of severe hypo-
glycemia is reported in Table 1 and Table 2. Severe 
hypoglycemia was defined per the Diabetes Control 
and Complications Trials as “an event requiring the 
assistance of another person, including aid in ingest-
ing an oral carbohydrate, administering a glucagon 
injection or intravenous glucose”24 in seven of the tri-
als reviewed.
Place in Therapy
Based on the information obtained from these studies, 
pramlintide may be an option for patients needing 
pharmacologic assistance for weight loss; however, 
further research needs to be conducted to determine 
efficacy in obese patients without diabetes. There 
are several drawbacks to the use of pramlintide, 
including the fact that it is an injectable medication. 
The medication does cause nausea in many patients 
which may lead to discontinuation of the drug. In the 
studies conducted, nausea was frequent; however, 
it subsided over time with continued use. Symlin is 
available as a SymlinPen® in strengths of 60 mcg and 
120 mcg and as a multi-dose vial. The cost of the 
pen is as follows: SymlinPen® 120(2 syringes, 2.7 ml 
each), $293.93, which may limit its use for certain 
patients.25 The cost of a multi-dose vial is less expen-
sive, 0.6 mg/ml (5 ml, $189.74); however, it requires 
a conversion from mcg to units in order to use an 
insulin syringe. The conversion could attribute to 
medication errors.
There are very few therapeutic options for the man-
agement of obesity. Since obesity can attribute to and 
worsen numerous other medical conditions, it is impor-
tant to identify products to help patients lose weight. 
Pramlintide is a relatively new product that deserves 
further study in order to determine if it is a viable 
option for the treatment of obesity.
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